Dedicated to improving care
Elevating Urology Through Clinical Research
Conducting clinical research keeps us at the forefront of urology treatment and gives our patients access to promising treatments and expert knowledge. This research enables us to offer our patients in Philadelphia and surrounding counties the latest advancements in treatments.
Each clinical research trial follows strict guidelines to protect participants. Ask your doctor if there’s a trial that is right for you. Or call our Clinical Research Department at 610-667-0458.
Sponsors and CROs: Learn more about partnering with MidLantic Urology for your next urology trial.
Clinical Trials at MidLantic Urology
Clinical research trials play an essential role in bringing new treatments to our patients. Those who participate in trials enjoy the reassurance and security they get from being closely monitored, and the satisfaction that they are playing an important role in advancing medicine.
These clinical trials are currently available at MidLantic Urology.
Benign Prostatic Hyperplasia
PRODEON - EXPANDER-2 TRIAL
A Randomized Study to Evaluate the Safety and Efficacy of the Urocross(TM) Expander System and Retrieval SheathLearn More
PROVERUM - PROVIDE
The ProVIDE clinical trial is a prospective, multi-center, double-blind controlled study to evaluate the safety, performance, and effectiveness of the ProVee System in patients with lower urinary tract symptoms secondary to BPH.
JANSSEN BLC2001 - (SUNRISE 1)
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with i. Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette- ii. Guerin (BCG) who are Ineligible for or Elected Not to Undergo Radical CystectomyLearn More
JANSSEN BLC3001 - (SUNRISE 2)
A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical CystectomyLearn More
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)Learn More
Phase 2 Window of Opportunity Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients with Recurrent Low- or Intermediate-Risk TumorsLearn More
This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival.Learn More
MERCK KEYNOTE- 676
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin in High-Risk Non-Muscle Invasive Bladder Cancer.Learn More
Intravesical Photodynamic Therapy (PDT) in BCG Refractory/Intolerant Non-Muscle Invasive Bladder Cancer (NMIBC) PatientsLearn More
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)Learn More
APPLAUD MEDICAL - CIP-0001
Acoustic Enhancer Research on Laser Lithotripsy (AEROLITH)Learn More
ASTRAZENECA – CAPITELLO
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency (CAPItello-281)Learn More
BAYER 21516 (ARASEC)
A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. (ARASEC)Learn More
CURIUM PHARMA - ECLIPSE
Lu-177-PSMA-I&T for Metastatic Castration-Resistant Prostate CancerLearn More
JANSSEN 3011 (PROTEUS STUDY)
A Study of Apalutamide in Participants With High‑Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (PROTEUS)Learn More
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants (PRIMORDIUM).Learn More
MLU1 - EMBRACE
MLU2 - PROMISE
MLU3 - CHARTED (ANGLE – ANG-015)
Characterization of Circulating Tumor Cells Isolated Using the Parsortix® System in High Risk and Early Metastatic Prostate Cancer PatientsLearn More
MLU4 - DOMINO (ANGLE - ANG-012)
MSK: DOCETAXEL & RADIUM -223 (DORA STUDY)
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer.Learn More
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate CancerLearn More
Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate CancerLearn More
Renal Cell Carcinoma
MERCK - MK-022
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)Learn More
For more information or to enroll in one of these trials, call MidLantic’s Clinical Research Department at 610-667-0458.
A Trusted Team
Clinical trials help scientists better understand disease and develop new medications, treatments, and devices. Our clinical research team is comprised of top physicians and specialists experienced in clinical research. We provide our patients with the opportunity to participate in clinical trials and gain access to the latest therapy and technology available to treat their urologic condition.
Led by Dr. Laurence Belkoff, D.O., F.A.C.O.S and Clinical Research Director Cheryl Zinar, RN, BSN, together oversee a dedicated research team of RNs, Research Assistants and Regulatory Specialists. Backed by a research committee of eight board certified physicians, we continually strive to advance urology health.